Assembly Biosciences (ASMB)
(Delayed Data from NSDQ)
$12.85 USD
-0.30 (-2.28%)
Updated May 6, 2024 04:00 PM ET
After-Market: $13.08 +0.23 (1.79%) 6:34 PM ET
2-Buy of 5 2
C Value A Growth D Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ASMB 12.85 -0.30(-2.28%)
Will ASMB be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ASMB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ASMB
Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?
TEVA Shares Rise on Broad Support for Opioids Settlement
ASMB: What are Zacks experts saying now?
Zacks Private Portfolio Services
After Plunging 17% in 4 Weeks, Here's Why the Trend Might Reverse for Assembly Biosciences (ASMB)
Assembly Biosciences (ASMB) Upgraded to Strong Buy: Here's Why
Best Momentum Stocks to Buy for August 4th
Other News for ASMB
Analysts Offer Insights on Healthcare Companies: Assembly Biosciences (ASMB), Natera (NTRA) and Disc Medicine (IRON)
H.C. Wainwright Sticks to Its Hold Rating for Assembly Biosciences (ASMB)
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
ASMB Stock Earnings: Assembly Biosciences Beats EPS for Q4 2023
Assembly Biosciences GAAP EPS of -$13.38 beats by $0.90